RU2019111768A - Противораковые агенты и их получение - Google Patents

Противораковые агенты и их получение Download PDF

Info

Publication number
RU2019111768A
RU2019111768A RU2019111768A RU2019111768A RU2019111768A RU 2019111768 A RU2019111768 A RU 2019111768A RU 2019111768 A RU2019111768 A RU 2019111768A RU 2019111768 A RU2019111768 A RU 2019111768A RU 2019111768 A RU2019111768 A RU 2019111768A
Authority
RU
Russia
Prior art keywords
alkyl
group
cancer
compound
formula
Prior art date
Application number
RU2019111768A
Other languages
English (en)
Russian (ru)
Other versions
RU2019111768A3 (enExample
Inventor
Арун К. ГХОШ
Original Assignee
Пердью Ресерч Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пердью Ресерч Фаундейшн filed Critical Пердью Ресерч Фаундейшн
Publication of RU2019111768A publication Critical patent/RU2019111768A/ru
Publication of RU2019111768A3 publication Critical patent/RU2019111768A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2019111768A 2016-09-23 2017-09-22 Противораковые агенты и их получение RU2019111768A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662398783P 2016-09-23 2016-09-23
US62/398,783 2016-09-23
PCT/US2017/052967 WO2018057897A1 (en) 2016-09-23 2017-09-22 Anti-cancer agents and preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2023103324A Division RU2023103324A (ru) 2016-09-23 2017-09-22 Противораковые агенты и их получение

Publications (2)

Publication Number Publication Date
RU2019111768A true RU2019111768A (ru) 2020-10-23
RU2019111768A3 RU2019111768A3 (enExample) 2020-11-24

Family

ID=61690726

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019111768A RU2019111768A (ru) 2016-09-23 2017-09-22 Противораковые агенты и их получение

Country Status (14)

Country Link
US (2) US10858371B2 (enExample)
EP (1) EP3515492B1 (enExample)
JP (1) JP7111722B2 (enExample)
KR (1) KR102646702B1 (enExample)
CN (1) CN109862916A (enExample)
AU (1) AU2017331260B2 (enExample)
BR (1) BR112019005885A2 (enExample)
CA (1) CA3037883A1 (enExample)
DK (1) DK3515492T3 (enExample)
IL (1) IL265521B2 (enExample)
MA (1) MA46291A (enExample)
MX (1) MX394670B (enExample)
RU (1) RU2019111768A (enExample)
WO (1) WO2018057897A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017331260B2 (en) 2016-09-23 2024-11-07 Purdue Research Foundation Anti-cancer agents and preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
US7825267B2 (en) * 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
WO2009031999A1 (en) * 2007-09-07 2009-03-12 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fr901464 and analogs with antitumor activity and method for their preparation
CN101417934B (zh) * 2007-10-24 2012-04-18 国鼎生物科技股份有限公司 分离自牛樟芝萃取物的化合物
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
WO2009155606A1 (en) * 2008-06-21 2009-12-23 St. Jude Children's Research Hospital Anticancer compounds and methods of making and using same
US20150025017A1 (en) * 2012-02-28 2015-01-22 Fred Hutchinson Cancer Research Center Compositions and methods for treating cancer
MX340090B (es) * 2012-11-05 2016-06-23 Pfizer Analogos de spliceostatina.
WO2014100367A1 (en) * 2012-12-21 2014-06-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Synthesis of fr901464 and analogs with antitumor activity
US20140274979A1 (en) * 2013-03-13 2014-09-18 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
CN105611930B (zh) 2013-07-15 2021-03-02 亥姆霍兹慕尼黑中心-德国环境与健康研究中心(股份有限公司) 作为非凋亡调控性细胞死亡抑制剂的螺环喹喔啉衍生物
KR102092569B1 (ko) * 2013-09-17 2020-03-25 엘지디스플레이 주식회사 터치 스크린 일체형 디스플레이 장치와 이의 구동 방법
US10000505B2 (en) 2013-11-19 2018-06-19 Purdue Research Foundation Anti-cancer agents and preparation thereof
EP3468976A4 (en) * 2016-06-08 2019-11-27 William Marsh Rice University DERIVATIVES OF THAILANSTATIN A, METHOD FOR THE TREATMENT AND METHOD FOR SYNTHESIS THEREOF
AU2017331260B2 (en) 2016-09-23 2024-11-07 Purdue Research Foundation Anti-cancer agents and preparation thereof

Also Published As

Publication number Publication date
KR102646702B1 (ko) 2024-03-11
IL265521A (en) 2019-05-30
IL265521B1 (en) 2024-05-01
WO2018057897A1 (en) 2018-03-29
IL265521B2 (en) 2024-09-01
US20190218228A1 (en) 2019-07-18
MA46291A (fr) 2019-07-31
US20210395265A1 (en) 2021-12-23
AU2017331260A1 (en) 2019-05-16
EP3515492A1 (en) 2019-07-31
CN109862916A (zh) 2019-06-07
JP2019529563A (ja) 2019-10-17
MX2019003368A (es) 2019-09-16
AU2017331260B2 (en) 2024-11-07
BR112019005885A2 (pt) 2020-06-02
CA3037883A1 (en) 2018-03-29
RU2019111768A3 (enExample) 2020-11-24
EP3515492B1 (en) 2023-07-26
KR20190077340A (ko) 2019-07-03
US11851441B2 (en) 2023-12-26
MX394670B (es) 2025-03-11
US10858371B2 (en) 2020-12-08
EP3515492A4 (en) 2020-04-08
DK3515492T3 (da) 2023-08-28
JP7111722B2 (ja) 2022-08-02

Similar Documents

Publication Publication Date Title
RU2018138828A (ru) Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами
RU2016130933A (ru) Сульфонамид-содержащие связывающие системы для лекарственных конъюгатов
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
RU2015119557A (ru) Конъюгаты лекарственное вещество-белок
JP2018511628A5 (enExample)
JP2018516243A5 (enExample)
RU2014145121A (ru) Пиримидиновые соединения для лечения злокачественной опухоли
JP2018507197A5 (enExample)
JP2020506951A5 (enExample)
RU2016120012A (ru) Ингибиторы рецептора фактора роста фибробластов
RU2013130250A (ru) Замещенные пуриновые и 7-деазапуриновые соединения
RU2015104342A (ru) Ингибиторы рецептора фактора роста фибробластов
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2013503139A5 (enExample)
JP2015517574A5 (enExample)
JP2015523380A5 (enExample)
RU2011118055A (ru) Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
RU2018129308A (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
RU2005132408A (ru) Ингибиторы киназы
RU2020102453A (ru) Фармацевтические композиции
RU2017131158A (ru) Конъюгат лиганда с цитотоксическим лекарственным средством, способ его получения и применение
RU2015119561A (ru) Новые конъюгаты лекарственное вещество-белок
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
JP2017510660A5 (enExample)
JP2021515032A5 (enExample)